scholarly journals Dipeptidyl Peptidase-4 Inhibitors and the Risk of Pancreatitis in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study

2018 ◽  
Vol 2018 ◽  
pp. 1-10 ◽  
Author(s):  
Young-Gun Kim ◽  
Seirhan Kim ◽  
Seung Jin Han ◽  
Dae Jung Kim ◽  
Kwan-Woo Lee ◽  
...  
Keyword(s):  
Acute Pancreatitis ◽  
Cohort Study ◽  
Proportional Hazards ◽  
National Sample ◽  
Dipeptidyl Peptidase ◽  
Population Based ◽  
Cox Proportional Hazards ◽  
Drug Induced ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitors

Background. Information on the risk of acute pancreatitis in patients receiving dipeptidyl-peptidase IV inhibitors (DPP-4i) is limited and controversial. One study suggested that the differences in findings between these meta-analyses were attributed to whether they included large randomized control trials with cardiovascular outcomes or not. The aim of our study was to determine whether the use of DPP-4i increases the risk of acute pancreatitis compared with sulfonylurea (SU) and whether the risk is higher in patients with underlying cardiovascular disease (CVD). Methods. A population-based cohort study was performed using Korean National Health Insurance Service-National Sample Cohort data. We included 33,395 new users of SU and DPP-4i from 1 January 2008 to 31 December 2015. SU-treated patients and DPP-4i-treated patients were matched by 1 : 1 propensity score matching. We used Kaplan–Meier curves and Cox proportional hazards regression analysis to calculate the risk of acute pancreatitis. Results. The hazard ratio (HR) of hospitalization for acute pancreatitis was 0.642 (95% confidence interval (CI): 0.535–0.771) in DPP-4i-treated patients compared with SU-treated patients. The HR of DPP-4i use was also lower than that of SU use in patients without underlying CVD (HR: 0.591; 95% CI: 0.476–0.735) but not in patients with underlying CVD (HR: 0.727; 95% CI: 0.527–1.003). Conclusion. Our findings suggest that DPP-4i is less likely to cause drug-induced pancreatitis than SU. This finding was not evident in patients with CVD, but DPP-4i was not more likely to induce pancreatitis in these patients than SU was.

Increased risk of bullous pemphigoid in dipeptidyl peptidase 4 inhibitors: A nationwide, population‐based, cohort study in Taiwan

2019 ◽  
Vol 47 (3) ◽  
pp. 245-250 ◽  
Author(s):  
Chih‐Tsung Hung ◽  
Jhih‐Syuan Liu ◽  
Cheng‐Yi Cheng ◽  
Chi‐Hsiang Chung ◽  
Chien‐Ping Chiang ◽  
...  
Keyword(s):  
Cohort Study ◽  
Bullous Pemphigoid ◽  
Dipeptidyl Peptidase ◽  
Population Based ◽  
Dipeptidyl Peptidase 4 ◽  
Increased Risk ◽  
Dipeptidyl Peptidase 4 Inhibitors

scholarly journals Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: A retrospective population-based cohort study

2017 ◽  
Vol 19 (3) ◽  
pp. 421-428 ◽  
Author(s):  
Johanna H. M. Driessen ◽  
Joop P. W. van den Bergh ◽  
Hein A. W. van Onzenoort ◽  
Ronald M. A. Henry ◽  
Hubert G. M. Leufkens ◽  
...  
Keyword(s):  
Cohort Study ◽  
Dipeptidyl Peptidase ◽  
Population Based ◽  
Risk Of Fracture ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitors

scholarly journals Risk of Cardiovascular Events and Medical Cost of Dapagliflozin and Dipeptidyl Peptidase-4 Inhibitors

2021 ◽  
Vol 12 ◽  
Author(s):  
Jong-Mi Seong ◽  
Jong Joo Kim ◽  
Hae Jin Kim ◽  
Hyun Soon Sohn
Keyword(s):  
Cohort Study ◽  
Medical Cost ◽  
Medical Costs ◽  
Dipeptidyl Peptidase ◽  
Population Based ◽  
Decision Analytic Model ◽  
Dipeptidyl Peptidase 4 ◽  
Direct Medical Costs ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
Insurance Claims Data

This study compared dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, and dipeptidyl peptidase-4 inhibitors (DPP-4i) with regard to cardiovascular (CV) event incidence and direct medical costs during type 2 diabetes treatment. A retrospective cohort study was conducted using national health insurance claims data from September 1, 2014, to June 30, 2018, of patients in Korea. Patients who were prescribed dapagliflozin and DPP-4i for the first time were included. The primary outcome was the incidence of a composite of major adverse CV events (MACEs)—nonfatal myocardial infarction, nonfatal stroke, or in-hospital CV death. Proportional hazard models after propensity score weighting were used to determine hazard ratios (HRs) and 95% confidence intervals (CIs) for MACE in the dapagliflozin and DPP-4i groups. A decision analytic model was used to compare direct medical costs between the two treatment groups from a healthcare provider’s perspective. Of the 260,336 patients in the cohort, 23,147 and 237,189 received dapagliflozin and DPP-4i, respectively. During the follow-up, 184 patients receiving dapagliflozin and 3,674 receiving DPP-4i (incidence, 6.47 and 11.33 events/1,000 person-years, respectively) had MACE. The adjusted HR of MACE for dapagliflozin compared with that for DPP-4i was 0.69 (95% CI 0.57–0.83). The corresponding HRs were consistent among patients with and without underlying CV disease. The estimated direct medical cost appeared to be lower by $68,452 in the dapagliflozin group than that in the DPP-4i group for 3 years, in 1,000 hypothetical patients. In this population-based cohort study, the use of dapagliflozin instead of DPP-4i was associated with a reduced risk of MACE, which subsequently reduced direct medical costs. These data provide valuable information to patients, practitioners, and authorities regarding the risk of CV events associated with dapagliflozin versus DPP-4i use in clinical practice.

scholarly journals Use of Dipeptidyl-Peptidase-4 Inhibitors and the Risk of Pneumonia: A Population-Based Cohort Study

PLoS ONE ◽  
2015 ◽  
Vol 10 (10) ◽  
pp. e0139367 ◽  
Author(s):  
Rogier Wvan der Zanden ◽  
Frank de Vries ◽  
Arief Lalmohamed ◽  
Johanna H. M. Driessen ◽  
Anthonius de Boer ◽  
...  
Keyword(s):  
Cohort Study ◽  
Dipeptidyl Peptidase ◽  
Population Based ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitors
Sign in / Sign up

Export Citation Format

Share Document